21/10/04

Why non-profit drug companies are needed

Drugs produced by non-profit companies could help tackle infectious diseases Copyright: WHO/P. Virot

We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:

You have to credit our authors.
You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
The easiest way to get the article on your site is to embed the code below.

For more information view our media page and republishing guidelines.

The full article is available here as HTML.

Press Ctrl-C to copy

<div class="article-wrap">
<div id="article-introduction">
<h1>Why non-profit drug companies are needed</h1>
<h4></h4>
</div>
<br />
<br />

<div id="article-body">
<p><P>Infection is the second biggest cause of death worldwide but even as resistance to antibiotics is growing, development of new drugs is in decline. Economic, regulatory and scientific factors contribute to the situation, which is converging with a scarcity of antibiotics to treat infectious diseases prevalent mainly in poor countries.</P><br />
<P>In this article in <em>Nature</em>, Carl Nathan<em> </em>of the Weill Graduate School of Medical Sciences of Cornell University outlines a “three-part vision” for addressing the situation. Regulatory demands and patent incentives should be revised, and researchers should start applying new technologies to antibiotic development, says Nathan.</P><br />
<P>Non-profit drug companies are of central importance, according to Nathan. These, he says, could license their intellectual property for free to agencies and companies that pledge to produce and distribute drugs at low cost to those with the greatest need. Some small non-commercial drug companies do exist, focusing on diseases such as malaria, leishmaniasis and tuberculosis. But, he adds, the number needs to be greatly increased to research the major infectious diseases being inadequately served by the pharmaceutical industry.</P><br />
<P><a  href="http://www.nature.com/login/scidev_login.taf?ref=/nature/journal/v431/n7011/full/431899a_fs.html" target="_blank" onclick="pageTracker._trackPageview('/tracking/external/'+this.href);" rel="noopener noreferrer">Link to full article by Carl Nathan in <EM>Nature</EM></A></P>Reference: <em>Nature </em>431, 899 (2004)</p>

</div>
<div class="quick-links-wrapper">
<h3>You might also like</h3>
[related-articles]
</div>
<p>This article was originally published on <a href="https://www.scidev.net" target="_blank">SciDev.Net</a>. Read the <a href="https://www.scidev.net/global/opinions/why-nonprofit-drug-companies-are-needed/" target="_blank">original article</a>.</p>
<script type="text/javascript">
(function(e,t,n,r,i,s,o){e["GoogleAnalyticsObject"]=i;e[i]=e[i]||function(){(e[i].q=e[i].q||[]).push(arguments)},e[i].l=1*new Date;s=t.createElement(n),o=t.getElementsByTagName(n)[0];s.async=1;s.src=r;o.parentNode.insertBefore(s,o)})(window,document,"script","//www.google-analytics.com/ga.js","ga");var _gaq=_gaq||[];var _gaq=_gaq||[];_gaq.push(["_setAccount","UA-3223906-8"],["_trackEvent","article interaction","republished","https://www.scidev.net/global/opinions/why-nonprofit-drug-companies-are-needed/",null,true])
</script>
</div>

Infection is the second biggest cause of death worldwide but even as resistance to antibiotics is growing, development of new drugs is in decline. Economic, regulatory and scientific factors contribute to the situation, which is converging with a scarcity of antibiotics to treat infectious diseases prevalent mainly in poor countries.

In this article in Nature, Carl Nathan of the Weill Graduate School of Medical Sciences of Cornell University outlines a “three-part vision” for addressing the situation. Regulatory demands and patent incentives should be revised, and researchers should start applying new technologies to antibiotic development, says Nathan.

Non-profit drug companies are of central importance, according to Nathan. These, he says, could license their intellectual property for free to agencies and companies that pledge to produce and distribute drugs at low cost to those with the greatest need. Some small non-commercial drug companies do exist, focusing on diseases such as malaria, leishmaniasis and tuberculosis. But, he adds, the number needs to be greatly increased to research the major infectious diseases being inadequately served by the pharmaceutical industry.

Link to full article by Carl Nathan in Nature

Reference: Nature 431, 899 (2004)